DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial

Autor: L Peyrin-Biroulet, S Vermeire, G R D’Haens, J Panés, A Dignass, F Magro, M Le Bars, M Lahaye, M Nazar, L Ni, I Bravatà, F Lavie, M Daperno, M Lukáš, A Armuzzi, M Löwenberg, D R Gaya, S Danese

Publikováno v: Journal of Crohn's and Colitis. 16:i132-i134

Background STARDUST is a phase 3b randomized trial comparing two therapeutic strategies with ustekinumab (UST) in patients (pts) with Crohn’s disease (CD): treat-to-target (T2T) using early endoscopic assessment vs standard of care (SoC). Results f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c25e07d580c0eb78af27b0d10cb1bd1
https://doi.org/10.1093/ecco-jcc/jjab232.129

POS0072 CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS

Autor: I. Mcinnes, J. Tesser, E. Schiopu, J. F. Merola, S. D. Chakravarty, E. Rampakakis, N. Shiff, A. Kollmeier, X. L. Xu, M. Shawi, F. Lavie, P. Bird, P. J. Mease

Publikováno v: Annals of the Rheumatic Diseases. 81:253-254

BackgroundPsoriatic arthritis (PsA) patients (pts) with differing baseline (BL) characteristics may vary in their response to treatment. In the phase 3 DISCOVER-1 and DISCOVER-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69b8b0220822b2ee4b068cb66e474800
https://doi.org/10.1136/annrheumdis-2022-eular.47

Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO

Autor: Brian Kirby, P. Bergmans, Miriam Brunori, A. Castiglia, Lluís Puig, MA Radtke, Francesca Sampogna, Ph.I. Spuls, J. Rundle, Carle Paul, P Smirnov, F. Lavie, Giampiero Girolomoni

Publikováno v: BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
British journal of dermatology, 180(2), 397-403. Wiley-Blackwell

Background Alexithymia refers to difficulty in identifying and expressing emotions. Alexithymia is associated with high burden of disease in patients with psoriasis. Objectives To investigate whether alexithymia was reversible in patients with psoria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66806e768afdd9ed111ee06ef9dd7034
https://doi.org/10.1111/bjd.17259

POS1031 EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT

Autor: P. J. Mease, A. B. Gottlieb, A. Ogdie, I. Mcinnes, S. D. Chakravarty, E. Rampakakis, A. Kollmeier, X. L. Xu, M. Shawi, F. Lavie, M. Kishimoto, P. Rahman

Publikováno v: Annals of the Rheumatic Diseases. 81:828.2-829

BackgroundGuselkumab (GUS), an IL-23p19-subunit inhibitor, demonstrated efficacy and a favorable safety profile in patients (pts) with psoriasis (PsO) and psoriatic arthritis (PsA). In the Phase 3, double-blind, placebo (PBO)-controlled DISCOVER-2 st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2785f4a0e5ab1b8d6904c97b9264cf82
https://doi.org/10.1136/annrheumdis-2022-eular.1386

POS0074 IMMUNOLOGICAL DIFFERENCES BETWEEN PsA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS

Autor: S. Siebert, L. Coates, G. Schett, S. P. Raychaudhuri, W. Chen, S. Gao, S. D. Chakravarty, M. Shawi, F. Lavie, E. Theander, M. Neuhold, A. Kollmeier, X. L. Xu, P. Rahman, P. J. Mease, A. Deodhar

Publikováno v: Annals of the Rheumatic Diseases. 81:254.2-255

BackgroundA better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve & who have inadequate response to TNFi (TNFi-IR) may guide treatment choices. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80dc6d39321d969f7f39389acd3516d7
https://doi.org/10.1136/annrheumdis-2022-eular.892